ExPEC10V

BIOLOGICAL2 trials

Sponsors

Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.

Conditions

Extraintestinal Pathogenic Escherichia Coli PreventionHealthy

Phase 1

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

CompletedNCT03819049

Janssen Research & Development, LLCExtraintestinal Pathogenic Escherichia Coli Prevention

Start: 2019-06-06End: 2024-12-18Updated: 2025-05-25

A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese Adults

CompletedNCT04306302

Janssen Pharmaceutical K.K.Healthy

Start: 2020-03-13End: 2020-12-24Updated: 2021-01-20

Related Papers

Safety, reactogenicity, and immunogenicity of different doses of 10-valent Extraintestinal Pathogenic Escherichia Coli (ExPEC10V) bioconjugate vaccine (VAC52416) in healthy Japanese adults aged 60-85 years in a randomized, double-blind, phase 1 study.

2024-09-05

A randomized phase 1/2a trial of ExPEC10V vaccine in adults with a history of UTI

npj Vaccines2024-06-1413 citations

Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic <i>Escherichia coli</i> Bioconjugate Vaccine (VAC52416) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study

Open Forum Infectious Diseases2023-08-0126 citations

120. Safety, Reactogenicity, and Immunogenicity of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60–85 Years in a Randomized, Multicenter, Interventional, First-In-Human, Phase 1/2a Study

Open Forum Infectious Diseases2022-12-012 citations